Cell Sorting Market to Reach $3.09 Billion by 2035 at 12.4% CAGR | NanoCellect Biomedical, Fluidigm, LevitasBio Among Key Players

The global cell sorting market, valued at USD 903 million in 2025, will reach USD 1,078 million in 2026 and is on track to hit USD 3,085 million by 2035, growing at a CAGR of 12.4% over the forecast period. This growth reflects the convergence of accelerating cell therapy pipelines, rapid advances in microfluidics and buoyancy-activated sorting, and a sharp rise in clinical investment across oncology, immunotherapy, and regenerative medicine.

To explore the complete findings, request a free sample of the report at https://www.rootsanalysis.com/reports/novel-cell-sorting-and-separation-market-focus-on-acoustophoresis-buoy/request-sample.html

Market Overview
Cell sorting is the process of isolating one or more specific cell types from a heterogeneous biological sample based on physical or biological properties. It is a foundational step in a broad array of workflows, from basic research and cancer diagnostics to the manufacturing of CAR-T cell therapies and stem cell products. As the complexity of cell-based treatment modalities grows, the precision and throughput of sorting technologies have become critical differentiators for both clinical outcomes and manufacturing economics.

More than 1,300 active clinical trials related to cell and gene therapies are currently registered on ClinicalTrials.gov, representing a direct and growing demand signal for high-performance cell isolation and sorting systems. Public and private capital continues to flow into this space. In January 2025, SGS launched Germany's first commercial fluorescence-activated cell sorting service for the biopharmaceutical industry, targeting cell and gene therapy developers. In November 2025, Akadeum Life Sciences submitted a Type II Drug Master File to the U.S. FDA for its GMP BACS Microbubble Cell Separation products, citing up to 40% cost savings in cell therapy manufacturing.

The breadth of applications, spanning hematopoiesis, tumor cell characterization, sperm sorting, and single-cell genomics, means that innovation in this market creates commercial value across multiple end markets simultaneously. That breadth is what makes the cell sorting market one of the more durable growth stories in the life sciences tools sector.

Key Growth Drivers
Rising clinical investment in cell-based therapeutics. The rapid expansion of CAR-T, TCR, and TIL therapies is generating sustained demand for precise, scalable cell isolation. With over 1,300 active cell and gene therapy trials globally, sorting instruments and consumables are now integral manufacturing inputs, not just research tools. In April 2026, AvenCell Therapeutics dosed the first patient in its Phase I QUADvance study with a CRISPR-engineered allogeneic CAR-T candidate, underscoring the pace of clinical progression in this segment.
Technological maturation of microfluidics and novel sorting modalities. Microfluidics currently holds approximately 60% of the cell sorting technology market, driven by its ability to deliver high-purity cell populations without the viability risks associated with older fluorescence-based methods. Buoyancy-activated cell sorting (BACS), which uses microbubbles and antibody interactions without requiring additional equipment, is advancing at a faster pace and will continue to gain share through 2035.

Growing demand for personalized medicine and single-cell analysis. Advances in single-cell sequencing and proteomics are pushing researchers to isolate rare, defined cell populations with greater precision. Induced pluripotent stem cells (iPSCs), which can be derived from a patient's own somatic cells, represent a particularly high-growth sub-segment, as they underpin autologous therapy development and patient-specific disease modeling.

Expansion of commercial manufacturing and contract service organizations. Commercial organizations currently account for approximately 40% of the end-user market, and this share is expanding. The establishment of dedicated cell therapy manufacturing facilities by pharmaceutical companies and CDMOs is creating durable, recurring demand for consumables, isolation kits, and automated sorting platforms.

Rising prevalence of cancer and HIV. Both conditions require sophisticated cell characterization for diagnosis, prognosis, and treatment monitoring. Circulating tumor cells currently account for the largest single cell type by sorting volume, representing approximately 50% of the market by type of cell sorted. Growing screening programs and the shift toward liquid biopsy in oncology are adding to this structural demand.

Market Segmentation
The cell sorting market segments across offering type, technology, cell type, cell size, application area, end user, and geography. By offering type, consumables and isolation kits hold the largest share at approximately 60% of the total market, and this segment also carries the highest CAGR of 12.4% through 2035. The recurrent purchase nature of consumables, combined with increasing demand for precision cell isolation methods and streamlined regulatory approvals, makes this the financially dominant sub-segment. Cell sorter instruments represent the remainder of the offering mix.

By application area, clinical diagnostics currently commands more than 50% of the market. Cell-based therapeutics is the fastest-growing sub-segment, propelled by the acceleration of CAR-T, stem cell, and TIL therapy programs. Among end users, commercial organizations lead with roughly 40% market share. By technology, microfluidics holds approximately 60% of the technology segment, though buoyancy-activated sorting is growing at the faster rate. Among cell sizes, the 5-10 μm range dominates due to handling ease and high-throughput compatibility, while the 10-15 μm range is the fastest-growing size sub-segment.

To request quote of this report, please visit:
https://www.rootsanalysis.com/reports/novel-cell-sorting-and-separation-market-focus-on-acoustophoresis-buoy/request-quote.html

Regional Insights
North America holds approximately 50% of the global cell sorting market and will maintain that leadership position through 2035. Roughly 60% of the companies offering cell sorters, isolation kits, and affiliated consumables are based in North America, creating a self-reinforcing ecosystem of developers, academic collaborators, and commercial customers. The region benefits from deep biopharmaceutical infrastructure, well-funded academic research centers, and a regulatory environment that has increasingly expedited approvals for cell and gene therapies.

Asia-Pacific is the fastest-growing regional market, with a projected CAGR of 10.5% through 2035. An aging population, rising awareness of precision medicine, and accelerating government investment in biomedical research are the primary drivers. Countries across the region are expanding their cell therapy manufacturing capabilities, creating new demand for sorting systems at both the research and clinical-grade production level. Europe rounds out the competitive geography, with SGS's launch of Germany's first commercial FACS service in 2025 highlighting the continent's growing role in cell therapy services.

Competitive Landscape
The cell sorting market currently features over 220 unique products, including cell sorters, isolation kits, consumables, and reagents, developed by a diverse set of players. Key companies profiled in the Roots Analysis report include NanoCellect Biomedical, Innovative Biochips, Cesca Therapeutics, Fluidigm, LumaCyte, Union Biometrica, LevitasBio, RareCyte, Cytonome, and Namocell.

The competitive structure skews toward smaller, specialized innovators, with the majority of developers employing fewer than 50 people. These companies are competing primarily on technology differentiation, particularly around label-free sorting, throughput speed, cell viability preservation, and instrument footprint. Partnerships and R&D agreements are the most common deal type in this space, as smaller innovators seek to validate their platforms and access distribution networks. More than 30% of cell sorters on the market use cell size and density as primary sorting criteria, while close to 45% of products rely on microfluidics. The battleground is shifting toward automation, GMP compliance, and regulatory readiness, as the cell therapy manufacturing market demands higher-throughput, audit-trail-capable systems.

Browse Full Report Description + Research Methodology + Table of Content + Infographics here:
https://www.rootsanalysis.com/reports/novel-cell-sorting-and-separation-market-focus-on-acoustophoresis-buoy/266.html

Contact Details
Gaurav Chaudhary
Email: Gaurav.chaudhary@rootsanalysis.com or sales@rootsanalysis.com
Website: https://www.rootsanalysis.com

About Roots Analysis
Roots Analysis is a global leader in the pharma / biotech market research. Having worked with over 750 clients worldwide, including Fortune 500 companies, start-ups, academia, venture capitalists and strategic investors for more than a decade, we offer a highly analytical / data-driven perspective to a network of over 450,000 senior industry stakeholders looking for credible market insights. All reports provided by us are structured in a way that enables the reader to develop a thorough perspective on the given subject. Apart from writing reports on identified areas, we provide bespoke research / consulting services dedicated to serve our clients in the best possible way.

This release was published on openPR.